Navigation Links
Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results
Date:11/3/2011

WALTHAM, Mass., Nov. 3, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that it will host a conference call and Webcast on Thursday, November 10 at 4:30 p.m. (EST) to discuss the Company's third quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.'s Website at http://www.ilgenetics.com.

About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).  For more information, please visit www.ilgenetics.com.Contacts:Media:

Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz MSL

Interleukin Genetics, Inc.781-684-0770

781-398-0700, ext. 1204interleukin@schwartzmsl.com

elurier@ilgenetics.com
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
2. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
3. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
4. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
5. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
6. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
7. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
8. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
9. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
10. Interleukin Genetics Reports Second Quarter 2009 Financial Results
11. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):